Survodutide (BI 456906, GLP-1/Glucagon Dual Agonist)
No pricing data available yet for this peptide.
Pricing data is updated regularly.
Survodutide is a dual glucagon/GLP-1 receptor agonist that combines the metabolic benefits of both pathways. GLP-1 agonism provides appetite suppression and improved insulin secretion, while glucagon agonism increases energy expenditure through hepatic lipid oxidation, thermogenesis, and fatty acid mobilization. This dual mechanism targets both energy intake and expenditure for enhanced weight loss and metabolic improvement, including potential benefits for metabolic-associated steatohepatitis (MASH).
| Level | Amount | Frequency | Timing |
|---|---|---|---|
| Beginner | 0.3 mg | Once weekly | Subcutaneous injection, escalate gradually |
| Standard | 2.4 mg | Once weekly | After dose escalation over 16 weeks |
| Advanced | 4.8 mg | Once weekly | Maximum dose after full escalation |
Ongoing; dose escalation over 16-20 weeks to maintenance
Approximately 64-96 hours
Pre-filled pen or syringe; no reconstitution needed
Refrigerate at 36-46°F, do not freeze
Pre-filled, use within labeled expiry
Explore peer-reviewed studies and clinical research on Survodutide
Peer-reviewed medical research
Active and completed clinical trials
Academic papers and citations
Evidence-based supplement analysis
Research Disclaimer: These links lead to external research databases. Always consult with a qualified healthcare provider before making decisions based on research literature.
This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment recommendation. Consult a licensed healthcare professional before using any peptide. BioProtocol does not sell peptides or pharmaceutical products.